MAP2 and melanoma: The regulatory sequences of MAP2 are progressively methylated during melanoma progression, suggesting MAP2 expression is silenced by epigenetic mechanism in metastatic melanoma [66] suggesting that treatment with demethylating agents such as 5’-azacytidine can be useful for melanoma, if used in appropriate combination with other agents.